CD19-targeted allogenic CAR-T cells therapy (AlloRunning Therapeutics)

N/A

Report date: 2026/01/07 20:01:01

Base Information

Drug NameCD19-targeted allogenic CAR-T cells therapy (AlloRunning Therapeutics)
Drug Alias Name19UCART
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAlloRunning Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAlloRunning Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A